Patients were randomly assigned in a 1:1 ratio to receive either aspirin 200 mg daily or a placebo for three years. Follow-up spanned five years, with regular clinical visits and recommended ...

A large-scale, international, multicentre, phase 3 clinical trial of aspirin for the secondary prevention of colorectal ...

A large trial shows aspirin does not significantly improve disease-free survival in patients with high-risk colorectal cancer ...

However, Tegtmeyer said it's not necessarily time to call it quits for investigating aspirin in this setting. "This was a small study," he told MedPage Today. "The use of 200 mg of aspirin daily ...

Led by Singapore, a 12-year, international, multi-centre, phase 3 clinical trial of aspirin for the secondary prevention of colorectal cancer in over 1,500 patients has been completed and published in ...